Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Market

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease, is a group of rare neurological diseases that mainly involve the nerve cells, responsible for controlling voluntary muscle movement. 


Amyotrophic Lateral Sclerosis Epidemiological Segmentation

 

The Epidemiological Segmentation of ALS in 7MM from 2017 to 2030 is segmented as:-

 

  • Total Prevalent Population of Amyotrophic Lateral Sclerosis
  • Gender-Specific Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis
  • Total Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis
  • Mutation-Specific Distribution by Amyotrophic Lateral Sclerosis
  • Type-specific Distribution by Amyotrophic Lateral Sclerosis
  • Age-specific Distribution by Amyotrophic Lateral Sclerosis
  • Site of Onset of Amyotrophic Lateral Sclerosis


Amyotrophic Lateral Sclerosis Epidemiology (2017)

 

  •  The total diagnosed Amyotrophic Lateral Sclerosis prevalent population in 7MM was 70,456.
  • The Gender-specific prevalence of Amyotrophic Lateral Sclerosis was observed in the United States:-
  • Males- 10,855 cases
  • Females- 6,940 cases
  • The total diagnosed prevalent cases of ALS in the United States were found to be 17,794.
  • The Age-specific cases of Amyotrophic Lateral Sclerosis were observed in the United States:-
  •   60–69 age group - 5,623
  • <20 age group - 94  

 

Amyotrophic Lateral Sclerosis Market

The therapeutic market size of ALS in 7MM in 2017 was USD USD 233.45 million.

 

Amyotrophic Lateral Sclerosis Market Drivers


  • Availability of genuine epidemiological data
  • Robust pipeline activity
  • Increasing awareness programs


Amyotrophic Lateral Sclerosis Market Barriers


  • High medical cost
  • Lack of proper diagnosis
  • High mortality rate
  • The dominance of a few drugs for the treatment


Amyotrophic Lateral Sclerosis Emerging Drugs

 

The emerging drugs of the Amyotrophic Lateral Sclerosis market are:


  • Arimoclomol
  • Tofersen (BIIB067)
  • Levosimendan
  • NurOwn (MSC-NTF cells)
  • Masitinib
  • Ultomiris (ravulizumab)
  • Tirasemtiv
  • Verdiperstat
  • Ibudilast (MN-166)
  • AMX0035
  • Zilucoplan
  • Gold Nanocrystals/CNM-Au8
  • Cromolyn sodium (ALZT-OP1a)
  • Reldesemtiv
  • RNS60
  • ANX005
  • PU-AD
  • Ezogabine/Potiga/Retigabine
  • Pegcetacoplan (APL-2)

And many more

 

Amyotrophic Lateral Sclerosis Key Players

 

The key players in the Amyotrophic Lateral Sclerosis market are:


  • Orphazyme
  • Biogen
  • Orion Pharma
  • Brainstorm Cell Therapeutics
  • AB Science
  • Alexion Pharmaceuticals
  • Cytokinetics
  • Biohaven Pharmaceuticals
  • MediciNova
  • Amylyx Pharmaceuticals
  • UCB Pharma
  • Clene Nanomedicine
  • AZTherapies
  • Cytokinetics/Astellas Pharma
  • Revalesio Corporation
  • Annexon
  • Samus Therapeutics
  • GlaxoSmithKline
  • Apellis Pharmaceuticals

And many more